Prevalence
Clinical
features
Differential
Diagnosis
Investigations
Therapy
Prevention
Prognosis
|  |  | | Therapy |
There is no clear benefit from
-
ciprofloxacin in Crohn's disease d
-
metronidazole in ulcerative colitis d
-
vancomycin d
-
anti-tuberculous therapy for Crohn's disease a
Why?
-
Vancomycin does not clearly prevent surgery or subsquent relapses in active Crohn's disease or ulcerative colitis.
d
-
Anti-TB therapy does not reduce stricture formation, surgery or steroid use in Crohn's disease. It also causes side-effects.
a
Anti-tuberculosis therapy causes adverse effects
| Patient |
Treatment |
Comparison |
Outcome |
CER |
RRR (95% CI) |
NNH
(95% CI) |
Crohn's disease
a
|
anti-TB chemotherapy
|
placebo
|
adverse effects
at
2
years
|
4.8%
|
-470%
(-1700% to
-75%)
|
5
(3 to
10)
|
|